No products in the cart
CJC-1295 DAC (5mg)
CJC-1295 DAC peptides are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
What is the CJC-1295 DAC peptide?
CJC-1295 DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) that has the potential to enhance plasma levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Drug affinity complex (DAC) is an additive component that helps to prolong the half-life of CJC-1295 in plasma.
AKA: CJC 1295 with DAC
Molecular Formula: C152H252N44O42
Molecular Weight: 3647.954 g/mol
PubChem: CID 56841945
Researchers have created several synthetic modifications of growth hormone-releasing hormone (GHRH), which retain certain selective traits of the hormone while eliminating others. CJC-1295 happens to be one of such synthetic analogs that comprise the first 29 amino acids of GHRH. Interestingly, it happens to be a maleimide derivative of 1-29 residues of hGRF. This helps produce a GH secretagogue with greater solubility, which is easier to synthesize in larger volumes and appears to maintain the biological effects of GH.
CJC-1295 vs. CJC-1295 with DAC
CJC-1295 DAC shares similarities with other GHRH analogs like Sermorelin, as both are derivatives of the first 29 amino acids of GHRH. It is also closest to, but not identical, to modified GRF (1-29). The similarity and the fact that CJC-1295 was created along with DAC creates confusion between the peptides. Through a lysine linker, DAC is attached to CJC-1295 to protect the peptide during its circulation in the bloodstream. DAC facilitates the association of peptides with blood proteins such as albumin. This appears to enhance their half-life compared to similar peptides such as GRF (1-29).
CJC-1295 and Growth Hormone Release
The peptide is intended to trigger the release of GH, as it is a synthetic analog for the natural GHRH. Mice model experiments have reported that a single administration of the peptide may induce almost 2-10 times higher production of GH. GH expression appears to reach a maximum level after 2 hours of the peptide administration, and the effect is maintained up to about six days later. The peptide appears to maintain the natural physiological level of GH, unlike other secretagogues. In other words, CJC-1295 has the potential to perform as a physiological GHRH and maintain the natural biological high and low expression pattern in GH levels. CJC-1295 appears to maintain the physiological level of the hormone while enhancing its release in the blood. This effect would ensure that GH brings about the benefits without enhancing its adverse side effects. CJC-1295 has been studied in relation to physiological regulation of GH on protein synthesis, fat metabolism, blood sugar, hypertrophy, bone density, hyperplasia, and myocardial function.
CJC-1295 and Infertility
Studies from the early 1990s suggest that CJC-1295 and other GRF analogs may improve female infertility. Mice models of superovulation have proven that GH and IGF-1 levels increase in blood around the time of ovulation. Thus the treatment, including CJC-1295 and GRF analogs may promote ovulation in female patients, possibly through IGF-1 and GH expression cycle. The use of GH secretagogues like CJC-1295 may be sufficient to promote proper ovulation. Scientists have further suggested the use of these analogs to improve sperm production and thus treat male infertility, though proper research is required to test the hypothesis.
CJC-1295 and Growth
Research has suggested that CJC-1295 may restore the physiological release of GH in mice lacking normal GH physiology. Jette et al. notes that “CJC-1295, showed a 4-fold increase in GH area under the curve over a 2-h period.” The peptide may potentially be used to treat growth anomalies in different mammalian species. Maintenance of the circadian cycle of GH release happens to be crucial to bringing about appropriate production of downstream hormones, such as insulin-like growth factor-1 (IGF-1).
CJC-1295 DAC Peptide Summary
CJC-1295 is a growth hormone secretagogue that has been developed to possess a long half-life in plasma. It may help restore and maintain the inherent physiologic expression rhythm of GH. The peptide has been of less interest to researchers due to the prevalence of number of such hormone analogs and the proprietorship on the molecule structure. Interestingly, now as it can be manufactured at will, the peptide is expected to renew research interest, especially owing to its potential in infertility treatment. Experimental studies have documented mild adverse effects, low oral and fantastic subcutaneous availability in mice models. However, the dose administered to mice (per kg) does not scale up for human use.
- Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006. Epub 2006 Jul 5. PMID: 16822960.
- Gautam D, Jeon J, Starost MF, Han SJ, Hamdan FF, Cui Y, Parlow AF, Gavrilova O, Szalayova I, Mezey E, Wess J. Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth. Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6398-403. doi: 10.1073/pnas.0900977106. Epub 2009 Mar 30. PMID: 19332789; PMCID: PMC2662962.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.
- Guo S, Li Z, Yan L, Sun Y, Feng Y. GnRH agonist improves pregnancy outcome in mice with induced adenomyosis by restoring endometrial receptivity. Drug Des Devel Ther. 2018 Jun 7;12:1621-1631. doi: 10.2147/DDDT.S162541. PMID: 29922037; PMCID: PMC5995291.
- Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8. doi: 10.1210/en.2004-1286. Epub 2005 Apr 7. PMID: 15817669.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.